ELVN
NASDAQ · Pharmaceuticals
Enliven Therapeutics Inc
$34.51
+3.36 (+10.79%)
Financial Highlights (FY 2025)
Revenue
263.34M
Net Income
79.58M
Gross Margin
41.2%
Profit Margin
30.2%
Rev Growth
-0.5%
D/E Ratio
0.42
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 41.2% | 41.2% | 41.2% |
| Operating Margin | 33.5% | 32.0% | 31.2% |
| Profit Margin | 30.2% | 27.0% | 27.3% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 263.34M | 235.73M | 210.63M |
| Gross Profit | 108.41M | 97.04M | 86.71M |
| Operating Income | 88.19M | 75.50M | 65.77M |
| Net Income | 79.58M | 63.75M | 57.56M |
| Gross Margin | 41.2% | 41.2% | 41.2% |
| Operating Margin | 33.5% | 32.0% | 31.2% |
| Profit Margin | 30.2% | 27.0% | 27.3% |
| Rev Growth | -0.5% | +12.7% | -7.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 261.38M | 238.05M | 246.29M |
| Total Equity | 620.63M | 551.15M | 566.73M |
| D/E Ratio | 0.42 | 0.43 | 0.43 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 141.73M | 119.11M | 111.32M |
| Free Cash Flow | 52.28M | 61.02M | 35.31M |